Copyright
©The Author(s) 2021.
World J Clin Cases. Nov 6, 2021; 9(31): 9452-9468
Published online Nov 6, 2021. doi: 10.12998/wjcc.v9.i31.9452
Published online Nov 6, 2021. doi: 10.12998/wjcc.v9.i31.9452
Table 1 Baseline demographic data and clinical characteristics of patients included in the study
Covariate | Original patients (before matching) | PSM adjusted patients (after matching) | Missing data (%) | ||||
Non-SIC (n = 2533) | SIC (n = 997) | P value | Non-SIC (n = 809) | SIC (n = 809) | P value | ||
Age (yr) | 64.46 ± 15.39 | 68.42 ± 15.21 | 0.000 | 68.06 ± 14.34 | 67.86 ± 15.37 | 0.791 | 0.0 |
Gender (Male), n (%) | 1383 (54.6) | 634 (63.6) | 0.000 | 513 (63.4) | 510 (63.0) | 0.877 | 0.0 |
Height (cm) | 169.22 ± 10.52 | 169.74 ± 12.16 | 0.236 | 169.34 ± 10.74 | 169.74 ± 11.28 | 0.466 | 12.1 |
Weight (kg) | 84.19 ± 27.24 | 81.91 ± 25.49 | 0.027 | 80.74 ± 23.35 | 82.21 ± 26.16 | 0.233 | 6.2 |
BSA (m2) | 1.88 ± 0.45 | 1.86 ± 0.45 | 0.224 | 1.91 ± 0.33 | 1.93 ± 0.36 | 0.218 | 12.6 |
BMI (kg/m2) | 29.24 ± 8.77 | 28.85 ± 13.46 | 0.345 | 28.14 ± 7.69 | 28.59 ± 9.58 | 0.295 | 12.6 |
Temperature (℃) | 36.88 ± 0.77 | 36.84 ± 0.79 | 0.267 | 37.02 ± 0.79 | 36.85 ± 0.76 | 0.000 | 2.1 |
SBP (mmHg) | 111.42 ± 14.89 | 108.20 ± 14.05 | 0.000 | 110.55 ± 15.17 | 108.69 ± 14.21 | 0.011 | 1.6 |
DBP (mmHg) | 57.60 ± 10.08 | 57.69 ± 10.09 | 0.821 | 59.18 ± 10.22 | 57.90 ± 9.99 | 0.011 | 1.6 |
MAP (mmHg) | 73.20 ± 10.22 | 72.61 ± 10.15 | 0.130 | 75.09 ± 10.52 | 72.68 ± 9.96 | 0.000 | 1.5 |
HR (beats min-1) | 91.97 ± 17.38 | 92.32 ± 17.10 | 0.594 | 91.50 ± 17.23 | 92.41 ± 17.27 | 0.289 | 1.5 |
RR (min-1) | 21.20 ± 4.73 | 21.15 ± 4.45 | 0.789 | 21.32 ± 4.64 | 21.20 ± 4.46 | 0.572 | 1.5 |
SpO2 (%) | 96.84 ± 2.70 | 96.91 ± 2.92 | 0.458 | 96.75 ± 3.02 | 96.91 ± 2.75 | 0.269 | 1.6 |
SOFA score | 6.89 ± 3.88 | 7.02 ± 3.71 | 0.342 | 6.86 ± 3.72 | 6.99 ± 3.72 | 0.496 | 0.0 |
SAPS-I score | 20.90 ± 5.47 | 21.40 ± 5.36 | 0.013 | 22.03 ± 5.32 | 21.29 ± 5.27 | 0.005 | 0.0 |
SAPS-II score | 44.09 ± 15.43 | 46.57 ± 14.86 | 0.000 | 46.15 ± 15.18 | 46.32 ± 15.00 | 0.825 | 0.0 |
ECI | 13.76 ± 8.97 | 15.30 ± 8.73 | 0.000 | 14.56 ± 8.63 | 15.20 ± 8.83 | 0.142 | 0.0 |
Microbiology, n (%) | |||||||
Positive | 1387 (54.8) | 560 (56.2) | 0.448 | 463 (57.2) | 453 (56.0) | 0.616 | 0.0 |
Negative | 1146 (45.2) | 437 (43.8) | 346 (42.8) | 356 (44.0) | |||
Interventions, n (%) | |||||||
Renal replacement use (1st d) | 249 (9.8) | 120 (12.0) | 0.054 | 81 (10.0) | 98 (12.1) | 0.178 | 0.0 |
Mechanical ventilation use (1st d) | 1232 (48.6) | 516 (51.8) | 0.095 | 341 (42.2) | 414 (51.2) | 0.000 | 0.0 |
Comorbidities, n (%) | |||||||
Renal failure | 614 (24.2) | 324 (32.5) | 0.000 | 282 (34.9) | 249 (30.8) | 0.081 | 0.0 |
Liver failure | 418 (16.5) | 74 (7.4) | 0.000 | 17 (2.1) | 71 (8.8) | 0.000 | 0.0 |
Diabetes | 809 (31.9) | 424 (42.5) | 0.000 | 337 (41.7) | 333 (41.2) | 0.840 | 0.0 |
COPD | 552 (21.8) | 195 (19.6) | 0.144 | 186 (23.0) | 162 (20.0) | 0.146 | 0.0 |
Coagulopathy | 869 (34.3) | 317 (31.8) | 0.155 | 283 (35.0) | 255 (31.5) | 0.140 | 0.0 |
Admission type, n (%) | |||||||
Emergency | 2396 (94.6) | 960 (96.3) | 0.036 | 780 (96.4) | 785 (97.0) | 0.485 | 0.0 |
Elective | 137 (5.4) | 37 (3.7) | 29 (3.6) | 24 (3.0) | 0.0 | ||
Sepsis type, n (%) | |||||||
Sepsis | 548 (21.6) | 168 (16.9) | 0.003 | 174 (21.5) | 143 (17.7) | 0.064 | 0.0 |
Severe sepsis | 1315 (51.9) | 567 (56.9) | 411 (50.8) | 454 (56.1) | 0.0 | ||
Septic shock | 670 (26.5) | 262 (26.3) | 224 (27.7) | 212 (26.2) | 0.0 | ||
Laboratory tests | |||||||
WBC (109/L) | 16.50 ± 12.92 | 15.93 ± 9.65 | 0.206 | 17.15 ± 12.94 | 15.61 ± 9.17 | 0.006 | 0.3 |
Hemoglobin (g/dL) | 9.37 ± 1.88 | 9.57 ± 1.81 | 0.004 | 9.42 ± 1.91 | 9.57 ± 1.79 | 0.099 | 0.3 |
Platelet (109/L) | 195.01 ± 137.10 | 199.63 ± 124.20 | 0.356 | 202.55 ± 139.20 | 200.23 ± 125.24 | 0.725 | 0.2 |
Sodium (mmol/L) | 139.96 ± 5.62 | 140.04 ± 5.17 | 0.705 | 139.92 ± 5.59 | 140.02 ± 5.20 | 0.695 | 0.1 |
Potassium (mmol/L) | 3.78 ± 0.62 | 3.82 ± 0.60 | 0.064 | 3.76 ± 0.63 | 3.81 ± 0.61 | 0.094 | 0.1 |
Chloride (mmol/L) | 102.19 ± 7.57 | 102.09 ± 6.80 | 0.716 | 101.71 ± 7.25 | 102.25 ± 6.78 | 0.117 | 0.1 |
BUN (mg/dL) | 39.02 ± 27.97 | 43.79 ± 27.74 | 0.000 | 40.22 ± 27.95 | 42.90 ± 27.39 | 0.052 | 0.2 |
Creatine (mg/dL) | 2.21 ± 2.08 | 2.38 ± 2.02 | 0.023 | 2.43 ± 2.26 | 2.33 ± 2.04 | 0.389 | 0.1 |
Lactate (mmol/L) | 3.30 ± 2.77 | 3.59 ± 3.16 | 0.012 | 3.20 ± 2.55 | 3.46 ± 3.01 | 0.074 | 14.5 |
Albumin (g/dL) | 2.68 ± 0.67 | 2.78 ± 0.60 | 0.001 | 2.71 ± 0.66 | 2.76 ± 0.60 | 0.196 | 39.3 |
Bilirubin (mg/dL) | 3.69 ± 7.35 | 1.82 ± 3.58 | 0.000 | 2.70 ± 5.50 | 1.78 ± 3.57 | 0.001 | 25.6 |
PH | 7.34 ± 0.11 | 7.34 ± 0.11 | 0.358 | 7.34 ± 0.10 | 7.34 ± 0.11 | 0.592 | 27.3 |
PO2 (mmHg) | 132.70 ± 86.45 | 140.77 ± 92.91 | 0.037 | 128.11 ± 81.34 | 136.85 ± 90.36 | 0.081 | 27.2 |
PCO2 (mmHg) | 41.20 ± 14.08 | 39.92 ± 11.76 | 0.030 | 40.70 ± 14.25 | 39.81 ± 11.62 | 0.239 | 27.3 |
Bicarbonate (mmol/L) | 20.74 ± 5.61 | 20.32 ± 5.34 | 0.042 | 20.35 ± 5.49 | 20.32 ± 5.18 | 0.916 | 0.1 |
Glucose (mg/dl) | 140.88 ± 46.90 | 146.09 ± 51.54 | 0.004 | 145.48 ± 48.58 | 144.89 ± 48.96 | 0.808 | 1.6 |
CK-MB (%) | 6.83 ± 6.87 | 5.82 ± 6.00 | 0.063 | 6.87 ± 7.11 | 5.40 ± 5.64 | 0.037 | 80.7 |
CK (U/L) | 68.00 (31.00-194.00) | 74.50 (32.00-229.00) | 0.374 | 66.50 (30.00-212.25) | 76.00 (32.00-269.00) | 0.382 | 24.9 |
Troponin T (ng/mL) | 0.33 ± 1.06 | 0.38 ± 1.24 | 0.319 | 0.41 ± 1.41 | 0.39 ± 1.25 | 0.814 | 34.0 |
Table 2 Comparison of primary and secondary outcomes, n (%)
Outcome | Original patients (before matching) | PSM adjusted patients (after matching) | ||||||
Non-SIC (n = 2533) | SIC (n = 997) | OR (95%CI) | P value | Non-SIC (n = 809) | SIC (n = 809) | OR (95%CI) | P value | |
Hospital mortality | 818 (32.3) | 367 (36.8) | 1.22 (1.05-1.42) | 0.011 | 243 (30.0) | 286 (35.4) | 1.27 (1.03-1.57) | 0.023 |
Mechanical ventilation use | 1478 (58.3) | 619 (62.1) | 1.17 (1.01-1.36) | 0.042 | 431 (53.3) | 500 (61.8) | 1.42 (1.16-1.73) | 0.001 |
RRT use | 290 (11.4) | 116 (11.6) | 1.02 (0.81-1.28) | 0.876 | 91 (11.2) | 94 (11.6) | 1.04 (0.76-1.41) | 0.815 |
Norepinephrine use | 1276 (50.4) | 589 (59.1) | 1.42 (1.23-1.65) | 0.000 | 433 (53.5) | 474 (58.6) | 1.23 (1.01-1.50) | 0.040 |
Epinephrine use | 63 (2.5) | 62 (6.2) | 2.59 (1.81-3.70) | 0.000 | 25 (3.1) | 46 (5.7) | 1.88 (1.14-3.09) | 0.012 |
Dopamine use | 279 (11.0) | 188 (18.9) | 1.88 (1.54-2.30) | 0.000 | 105 (13.0) | 141 (17.4) | 2.08 (1.08-1.86) | 0.013 |
Vasopressin use | 508 (20.1) | 258 (25.9) | 1.39 (1.17-1.65) | 0.000 | 178 (22.0) | 206 (25.5) | 1.21 (0.96-1.52) | 0.102 |
Length of ICU stay (d) | ||||||||
Overall | 9.25 ± 11.66 | 9.11 ± 11.33 | NA | 0.749 | 9.35 ± 12.00 | 8.69 ± 9.74 | NA | 0.222 |
Survivors | 8.82 ± 12.00 | 8.70 ± 11.77 | 0.827 | 8.71 ± 11.85 | 8.25 ± 9.55 | 0.479 | ||
Non-Survivors | 10.15 ± 10.85 | 9.81 ± 10.51 | 0.616 | 10.82 ± 12.24 | 9.49 ± 10.03 | 0.167 | ||
Length of hospital stay (d) | ||||||||
Overall | 24.83 ± 26.05 | 21.45 ± 20.84 | NA | 0.000 | 23.38 ± 23.01 | 21.22 ± 19.46 | NA | 0.042 |
Survivors | 23.71 ± 23.69 | 21.92 ± 20.28 | 0.093 | 21.62 ± 19.17 | 21.40 ± 17.13 | 0.844 | ||
Non-Survivors | 27.19 ± 30.29 | 20.61 ± 21.75 | 0.000 | 27.44 ± 29.69 | 20.84 ± 23.13 | 0.004 |
Table 3 Baseline demographic data and clinical characteristics of patients with sepsis-induced cardiomyopathy
Covariate | Survivors (n = 630) | Non-survivors (n = 367) | P value | Missing data (%) |
Age (yr) | 67.26 ± 15.80 | 70.42 ± 13.97 | 0.002 | 0 |
Gender (Male), n (%) | 402 (63.8) | 232 (63.2) | 0.851 | 0 |
Height (cm) | 169.92 ± 12.52 | 169.44 ± 11.51 | 0.575 | 12.4 |
Weight (kg) | 83.44 ± 26.22 | 79.15 ± 23.91 | 0.014 | 6.7 |
BSA (m2) | 1.88 ± 0.46 | 1.83 ± 0.43 | 0.128 | 12.8 |
BMI (kg/m2) | 29.38 ± 15.02 | 27.92 ± 10.06 | 0.124 | 12.8 |
Temperature (℃) | 36.90 ± 0.73 | 36.74 ± 0.88 | 0.002 | 2.9 |
SBP (mmHg) | 109.72 ± 13.65 | 105.59 ± 14.34 | 0 | 1.9 |
DBP (mmHg) | 58.36 ± 9.67 | 56.53 ± 10.70 | 0.006 | 1.9 |
MAP (mmHg) | 73.32 ± 9.62 | 71.41 ± 10.91 | 0.005 | 1.8 |
HR (beats/min) | 91.36 ± 16.88 | 93.95 ± 17.38 | 0.022 | 1.8 |
RR (/min) | 20.98 ± 4.33 | 21.44 ± 4.65 | 0.119 | 1.8 |
SpO2 (%) | 97.19 ± 2.40 | 96.43 ± 3.60 | 0 | 2 |
SOFA score | 6.28 ± 3.38 | 8.29 ± 3.91 | 0 | 0 |
SAPS-I score | 20.37 ± 4.89 | 23.19 ± 5.66 | 0 | 0 |
SAPS-II score | 42.90 ± 13.54 | 52.87 ± 14.94 | 0 | 0 |
ECI | 14.36 ± 8.47 | 16.92 ± 8.93 | 0 | 0 |
Microbiology, n (%) | ||||
Positive | 354 (56.2) | 206 (56.1) | 0.985 | 0 |
Negative | 276 (43.8) | 161 (43.9) | ||
Interventions, n (%) | ||||
Renal replacement use (1st 24 h) | 69 (11.0) | 51 (13.9) | 0.168 | 0 |
Mechanical ventilation use | 296 (47.0) | 220 (59.9) | 0 | 0 |
Comorbidities, n (%) | ||||
Renal failure | 189 (30.0) | 135 (36.8) | 0.027 | 0 |
Liver failure | 46 (7.3) | 28 (7.6) | 0.849 | 0 |
Diabetes | 272 (43.2) | 152 (41.4) | 0.588 | 0 |
COPD | 117 (18.6) | 78 (21.3) | 0.303 | 0 |
Coagulopathy | 172 (27.3) | 145 (39.5) | 0 | 0 |
Admission type, n (%) | ||||
Emergency | 608 (96.5) | 352 (95.9) | 0.632 | 0 |
Elective | 22 (3.5) | 15 (4.1) | 0 | |
Sepsis type, n (%) | ||||
Sepsis | 143 (22.7) | 25 (6.8) | 0 | 0 |
Severe sepsis | 336 (53.3) | 231 (62.9) | 0 | |
Septic shock | 151 (24.0) | 111 (30.2) | 0 | |
Laboratory tests | ||||
WBC (109/L) | 15.88 ± 9.23 | 16.03 ± 10.36 | 0.809 | 0.1 |
Hemoglobin (g/dL) | 9.56 ± 1.84 | 9.59 ± 1.76 | 0.812 | 0.2 |
Platelet (109/L) | 214.36 ± 127.73 | 174.26 ± 113.66 | 0 | 0.1 |
Sodium (mmol/L) | 140.05 ± 4.93 | 140.03 ± 5.58 | 0.965 | 0 |
Potassium (mmol/L) | 3.78 ± 0.61 | 3.88 ± 0.59 | 0.018 | 0 |
Chloride (mmol/L) | 102.26 ± 6.58 | 101.78 ± 7.18 | 0.287 | 0.1 |
BUN (mg/dL) | 39.46 ± 24.07 | 51.24 ± 31.80 | 0 | 0.2 |
Creatine (mg/dL) | 2.23 ± 1.94 | 2.63 ± 2.13 | 0.003 | 0.2 |
Lactate (mmol/L) | 2.98 ± 2.12 | 4.62 ± 4.19 | 0 | 14.1 |
Albumin (g/dL) | 2.83 ± 0.58 | 2.69 ± 0.61 | 0.004 | 39.8 |
Bilirubin (mg/dL) | 1.49 ± 3.16 | 2.34 ± 4.10 | 0.002 | 26.8 |
PH | 7.35 ± 0.11 | 7.32 ± 0.12 | 0.001 | 26.3 |
PO2 (mmHg) | 142.73 ± 93.83 | 137.98 ± 91.67 | 0.495 | 26.3 |
PCO2 (mmHg) | 40.36 ± 10.79 | 39.30 ± 13.01 | 0.23 | 26.3 |
Bicarbonate | 21.01 ± 5.00 | 19.13 ± 5.69 | 0 | 0.1 |
(mmol/L) | ||||
Glucose (mg/dL) | 144.45 ± 47.67 | 148.89 ± 57.53 | 0.193 | 1.8 |
CK-MB (%) | 5.73 ± 5.64 | 6.00 ± 6.73 | 0.767 | 78.5 |
CK (U/L) | 413.37 ± 1425.54 | 313.84 ± 842.98 | 0.284 | 22.4 |
Troponin (ng/mL) | 0.42 ± 1.41 | 0.31 ± 0.87 | 0.264 | 33.4 |
Outcomes, n (%) | ||||
Mechanical ventilation use | 343 (54.4) | 276 (75.2) | 0 | 0 |
RRT use | 44 (7.0) | 72 (19.6) | 0 | 0 |
Norepinephrine use | 322 (51.1) | 267 (72.8) | 0 | 0 |
Epinephrine use | 27 (4.3) | 35 (9.6) | 0.001 | 0 |
Dopamine use | 94 (14.9) | 94 (25.6) | 0 | 0 |
Vasopressin use | 95 (15.1) | 163 (44.4) | 0 | 0 |
Length of ICU stay (d) | 8.71 ± 11.77 | 9.81 ± 10.51 | 0.138 | 0 |
Length of hospital stay (d) | 21.94 ± 20.29 | 20.61 ± 21.75 | 0.332 | 0 |
Table 4 Multivariate logistic analysis of risk factors for sepsis-induced cardiomyopathy
Covariate | OR | 95%CI | P value |
Age | 1.012 | 1.006-1.017 | 0.000 |
Male | 1.498 | 1.264-1.776 | 0.000 |
ECI | 1.036 | 1.025-1.046 | 0.000 |
Hemoglobin | 1.067 | 1.020-1.116 | 0.005 |
MV use1 | 1.003 | 1.000-1.006 | 0.041 |
Diabetes | 1.538 | 1.298-1.823 | 0.000 |
Liver failure | 0.340 | 0.251-0.459 | 0.000 |
SBP | 0.983 | 0.977-0.989 | 0.000 |
Table 5 Multivariate logistic regression analysis for risk factors of hospital death in sepsis-induced cardiomyopathy patients
Covariate | OR | 95%CI | P value |
Lactate | 1.107 | 1.038-1.180 | 0.002 |
SAPS-II score | 1.035 | 1.021-1.049 | 0.000 |
Sepsis types | 1.386 | 1.066-1.801 | 0.015 |
BUN | 1.009 | 1.003-1.015 | 0.006 |
SBP | 0.986 | 0.973-1.000 | 0.044 |
Platelet level | 0.998 | 0.997-1.000 | 0.031 |
- Citation: Liang YW, Zhu YF, Zhang R, Zhang M, Ye XL, Wei JR. Incidence, prognosis, and risk factors of sepsis-induced cardiomyopathy. World J Clin Cases 2021; 9(31): 9452-9468
- URL: https://www.wjgnet.com/2307-8960/full/v9/i31/9452.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i31.9452